# US 2026/0266837 A1 · Methods for Cancer Recurrence Detection and Treatment Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0266837 A1
- Document ID: US20260266837A1
- Status: Published application
- Kind: A1
- Application number: 18/722,488
- Filed: 2023-01-03
- Published: 2026-09-10
- Earliest claimed: 2022-01-03
- Assignees: Institut Curie; Centre National De La Recherche Scientifique; Sorbonne Universite
- Applicants: Institut Curie; Centre National de la Recherche Scientifique; Sorbonne Universite
- Inventors: Céline VALLOT; Justine MARSOLIER; Léa BAUDRE; Pacôme PROMPSY
- Web page: https://patentgrep.com/patent/US20260266837A1

## CPC

- G01N 33/575: for cancer
- G01N 33/6875: {Nucleoproteins}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 33/57585: {involving compounds identifiable in body fluids}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2333/4727: Calcium binding proteins, e.g. calmodulin
- G01N 2333/4742: Keratin; Cytokeratin
- G01N 2333/904: acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
- G01N 2333/91017: with definite EC number (2.1.1.-)
- G01N 2800/54: Determining the risk of relapse
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- G01N 2800/7028: Cancer
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The application concerns means for determining the risk of cancer recurrence in a human subject, in particular when the patient has or had therapy against cancer. In particular, the means of the invention involve determining the levels of expression of selected biomarkers, said selected biomarkers being selected among S100A2, LDHB, KRT14, TAGLN, NNMT, FOXQ1, FOSL1, NR2F2, KLF4 and TFCP2L1 in a sample previously obtained from the subject, and identifying the presence of persister cells within the sample when cancer cells express at least one of the selected biomarkers. The means of the invention also involve determining the presence or absence of persister cells, wherein persister cells has a quantity of H3K27me3 lower than a reference level. The invention also relates to method for treating patient who has or had cancer, and for preventing cancer recurrence in a patient who had or has cancer.

## Claims

### Claim 1

A method for determining a risk of cancer recurrence in a human subject who had or has a cancer, wherein the method comprises the steps of:
determining in cancer cell, optionally tumor cells exposed to a chemotherapeutic agent, issued from a biological sample previously obtained from the subject whether at least one genetic biomarker selected from the group comprising or consisting of LDHB, S100A2, KRT14, TAGLN, NNMT, FOXQ1, FOSL1, NR2F2, KLF4 and TFCP2L1 is over-expressed as compared to a reference level,
identifying the presence of persister cell in the biological sample as cancer cell over-expressing at least one genetic biomarker, optionally all genetic biomarkers, which expression has been measured,
classifying the subject as being at risk to have cancer recurrence when persister cell has been identified in the biological sample.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the persister cell over expresses:
at least LDHB and S100A2; and/or
at least KRT14, TAGLN, and NNMT; and/or
at least FOSL1 and KLF4, optionally at least FOXQ1, FOSL1, NR2F2 and KLF4, FOXQ1, FOSL1, NR2F2, KLF4 and TFCP2L1.

### Claim 3 (depends on 1)

The method according to claim 1 wherein the expression of at least LDHB and S110A2 is determined, optionally wherein the expression of all genetic biomarkers is determined.

### Claim 4 (depends on 3)

The method according to claim 3, wherein persister cells over-express all genetic biomarkers from the list consisting of S100A2, LDHB, KRT14, TAGLN, NNMT, FOXQ1, FOSL1, NR2F2, KLF4 and TFCP2L1.

### Claim 5 (depends on 1)

The method according to claim 1, further comprising the quantification of H3K27me3 within the cancer cell, optionally the quantification of H3K27me3 associated with the promoter of at least one gene encoding a genetic biomarker selected from the group comprising or consisting of LDHB, S100A2, KRT14, TAGLN, NNMT, FOXQ1, FOSL1, NR2F2, KLF4 and TFCP2L1.

### Claim 6

A method for determining a risk of cancer recurrence in a human subject who had or has a cancer, wherein the method comprises the steps of:
determining in cancer cell, optionally tumor cells exposed to a chemotherapeutic agent, issued from a biological sample previously obtained from the subject the presence or the absence of persister cells, wherein a persister cell has a quantity of H3K27me3 lower than a reference level,
classifying the subject as being at risk to have cancer recurrence when persister cells have been identified in the biological sample.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the subject had or has a cancer selected from the list consisting of bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colon cancer, esophageal cancer, gastric cancer, head & neck cancers, hodgkin's lymphoma, leukemia, liver cancer, lung cancer, melanoma, mesothelioma, multiple myeloma, myelodysplastic syndrome, non-hodgkin's lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cancer, sarcoma, skin cancer, testicular cancer, thyroid cancer or uterine cancer, optionally a breast cancer, or a Triple-Negative Breast Cancer (TNBC).

### Claim 8

A method for measuring the presence or absence of persister cells within a biological sample comprising cancer cells, optionally tumor cells exposed to a chemotherapeutic agent, issued from a biological sample previously obtained from at least one patient who has or had a cancer, wherein the method comprises:
determining in cancer cell whether at least one genetic biomarker selected from the group comprising or consisting of S100A2, LDHB, KRT14, TAGLN, NNMT, FOXQ1, FOSL1, NR2F2, KLF4 and TFCP2L1 is over-expressed as compared to a reference level,
identifying the presence of persister cell in the biological sample as cancer cell over-expressing at least one genetic biomarker, optionally all genetic biomarkers, which expression has been measured, or the absence of persister cells in the biological sample as no cancer cell over-expressing the genetic biomarker(s) which expression has been measured.

### Claim 9

A method for treating a human subject who had or has a cancer, said method comprising:
determining in cancer cell, optionally tumor cells exposed to a chemotherapeutic agent, issued from a biological sample previously obtained from the subject whether at least one genetic biomarker selected from the group comprising or consisting of S100A2, LDHB, KRT14, TAGLN, NNMT, FOXQ1, FOSL1, NR2F2, KLF4 and TFCP2L1 is over-expressed as compared to a reference level,
identifying the presence of persister cell in the biological sample as cancer cell over-expressing the one or more genetic biomarkers, optionally all genetic biomarkers, which expression has been measured,
when persister cell has been identified in the biological sample, administering to the subject an inhibitor of lysine demethylase or histone demethylase, optionally an inhibitor of lysine demethylase 6, of lysine demethylase 6 A/B or of H3K27me3 demethylase; and/or administering to the subject an inhibitor of S100A2, LDHB, KRT14, TAGLN, NNMT, FOXQ1, FOSL1, NR2F2, KLF4 or TFCP2L1.

### Claim 10 (depends on 9)

The method according to claim 9, wherein persister cell expresses at least:
S100A2 and LDHB; and/or
at least KRT14, TAGLN, and NNMT; and/or
at least FOSL1 and KLF4, optionally at least FOXQ1, FOSL1, NR2F2 and KLF4, FOXQ1, FOSL1, NR2F2, KLF4 and TFCP2L1,
S100A2, LDHB, KRT14, TAGLN, NNMT, FOXQ1, FOSL1, NR2F2, KLF4 and TFCP2L1.

### Claim 11

A method for treating or preventing cancer recurrence in a human subject who had or has a cancer, said method comprising:
determining in cancer cell, optionally tumor cells exposed to a chemotherapeutic agent, issued from a biological sample previously obtained from the subject whether at least one genetic biomarker selected from the group comprising or consisting of S100A2, LDHB, KRT14, TAGLN, NNMT, FOXQ1, FOSL1, NR2F2, KLF4 and TFCP2L1 is over-expressed as compared to a reference level,
identifying the presence of persister cell in the biological sample as cancer cell over-expressing the one or more genetic biomarkers, optionally all genetic biomarkers, which expression has been measured,
when persister cells have been identified within the biological sample, administering to the subject an inhibitor of lysine demethylase or histone demethylase, optionally an inhibitor of lysine demethylase 6, of lysine demethylase 6 A/B or of H3K27me3 demethylase and/or administering to the subject an inhibitor of S100A2, LDHB, KRT14, TAGLN, NNMT, FOXQ1, FOSL1, NR2F2, KLF4 or TFCP2L1.

### Claim 12 (depends on 9)

The method according to claim 9, wherein the subject has or had a cancer selected from the group consisting of bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colon cancer, esophageal cancer, gastric cancer, head & neck cancers, hodgkin's lymphoma, leukemia, liver cancer, lung cancer, melanoma, mesothelioma, multiple myeloma, myelodysplastic syndrome, non-hodgkin's lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cancer, sarcoma, skin cancer, testicular cancer, thyroid cancer or uterine cancer, optionally a breast cancer, and or a Triple-Negative Breast Cancer (TNBC).

### Claim 13

A method for preventing or reducing cancer recurrence by targeting persister cells with an effective amount of a chemotherapeutic agent and an inhibitor of lysine demethylase, optionally an inhibitor of lysine demethylase 6, more of lysine demethylase 6 A/B or of H3K27me3 demethylase.

### Claim 14

A method for reducing the number of persister cells upon chemotherapy exposure comprising administering to a patient in need thereof an effective amount of an inhibitor of lysine demethylase, optionally an inhibitor of lysine demethylase 6, of lysine demethylase 6 A/B or of H3K27me3 demethylase.

### Claim 15 (depends on 9)

The method according to claim 9, wherein the inhibitor is administered in combination with a chemotherapeutic agent, optionally simultaneously, wherein the chemotherapeutic agent a thymidylate synthase (TS) inhibitor,

### Claim 16 (depends on 1)

A kit for performing the method according to claim 1.

### Claim 17 (depends on 16)

The kit according to claim 16, which comprises reagents for measuring the expression of at least one genetic biomarker selected from the group comprising or consisting of LDHB, S100A2, KRT14, TAGLN, NNMT, FOXQ1, FOSL1, NR2F2, KLF4 and TFCP2L1 in a sample previously obtained from a human subject who had or has a cancer.
